| 1 |
23284223 |
10.1358/dof.2011.036.04.1588554 |
2022 |
Fostamatinib Disodium. |
SYK |
| 2 |
29721381 |
10.1080/2162402X.2017.1423183 |
2022 |
FOXO1 promotes resistance of non-Hodgkin lymphomas to anti-CD20-based therapy. |
SYK |
| 3 |
32042774 |
10.21037/atm.2019.11.71 |
2022 |
Upregulated <i>miR-155</i> inhibits inflammatory response induced by <i>C. albicans</i> in human monocytes derived dendritic cells via targeting p65 and BCL-10. |
SYK |
| 4 |
32587490 |
10.4103/sjmms.sjmms_300_19 |
2022 |
Systematic Analysis of Spleen Tyrosine Kinase Expression and its Clinical Outcomes in Various Cancers. |
SYK |
| 5 |
34147695 |
10.1016/j.jmoldx.2021.04.013 |
2022 |
Detection of Gene Fusion Transcripts in Peripheral T-Cell Lymphoma Using a Multiplexed Targeted Sequencing Assay. |
SYK |
| 6 |
34193976 |
10.1038/s41375-021-01326-x |
2022 |
Activated interleukin-7 receptor signaling drives B-cell acute lymphoblastic leukemia in mice. |
SYK |
| 7 |
34467417 |
10.1007/s00262-021-03043-x |
2022 |
Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype. |
SYK |
| 8 |
34890905 |
10.1016/j.neo.2021.12.001 |
2022 |
DCZ0014, a novel compound in the therapy of diffuse large B-cell lymphoma via the B cell receptor signaling pathway. |
SYK |
| 9 |
34993136 |
10.3389/fonc.2021.771669 |
2022 |
The Determinants of B Cell Receptor Signaling as Prototype Molecular Biomarkers of Leukemia. |
SYK |
| 10 |
35078814 |
10.1158/0008-5472.CAN-21-0218 |
2022 |
Targeting Cellular Iron Homeostasis with Ironomycin in Diffuse Large B-cell Lymphoma. |
SYK |
| 11 |
35197320 |
10.1124/jpet.121.000973 |
2022 |
ML355 Modulates Platelet Activation and Prevents ABT-737 Induced Apoptosis in Platelets. |
SYK |
| 12 |
35205606 |
10.3390/cancers14040860 |
2022 |
Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas. |
SYK |
| 13 |
35255496 |
10.1182/bloodadvances.2021006147 |
2022 |
A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas. |
SYK |
| 14 |
35296646 |
10.1038/s41419-022-04684-1 |
2022 |
Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma. |
SYK |
| 15 |
35398488 |
10.1016/j.cellsig.2022.110331 |
2022 |
SYK and ZAP70 kinases in autoimmunity and lymphoid malignancies. |
SYK |
| 16 |
35411950 |
10.1002/cbf.3702 |
2022 |
USP7 sustains an active epigenetic program via stabilizing MLL2 and WDR5 in diffuse large B-cell lymphoma. |
SYK |
| 17 |
35597428 |
10.1016/j.cellsig.2022.110358 |
2022 |
BTK-independent regulation of calcium signalling downstream of the B-cell receptor in malignant B-cells. |
SYK |
| 18 |
35605249 |
10.1182/bloodadvances.2022007695 |
2022 |
Latent membrane proteins from EBV differentially target cellular pathways to accelerate MYC-induced lymphomagenesis. |
SYK |
| 19 |
35681471 |
10.3390/cells11111777 |
2022 |
Pharmacological Inhibition of Spleen Tyrosine Kinase Suppressed Neuroinflammation and Cognitive Dysfunction in LPS-Induced Neurodegeneration Model. |
SYK |
| 20 |
23730399 |
10.6000/1927-7229.2012.01.01.1 |
2021 |
Targeting Mantle Cell Lymphoma with Anti-SYK Nanoparticles. |
SYK |
| 21 |
24851191 |
10.4236/jct.2014.51015 |
2021 |
SYK as a New Therapeutic Target in B-Cell Precursor Acute Lymphoblastic Leukemia. |
SYK |
| 22 |
31471373 |
10.3324/haematol.2019.216218 |
2021 |
CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. |
SYK |
| 23 |
31831562 |
10.1158/1078-0432.CCR-19-2202 |
2021 |
Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells. |
SYK |
| 24 |
32090646 |
10.1080/10428194.2020.1713317 |
2021 |
Diffuse large B-cell lymphoma with low <sup>18</sup>F-fluorodeoxyglucose avidity features silent B-cell receptor signaling. |
SYK |
| 25 |
32327472 |
10.1158/1078-0432.CCR-19-3239 |
2021 |
Phase I Study of TAK-659, an Investigational, Dual SYK/FLT3 Inhibitor, in Patients with B-Cell Lymphoma. |
SYK |
| 26 |
32341085 |
10.26508/lsa.202000700 |
2021 |
Immunoglobulin expression in the endoplasmic reticulum shapes the metabolic fitness of B lymphocytes. |
SYK |
| 27 |
32414848 |
10.3324/haematol.2019.241729 |
2021 |
Combinatorial efficacy of entospletinib and chemotherapy in patient-derived xenograft models of infant acute lymphoblastic leukemia. |
SYK |
| 28 |
32688206 |
10.1016/j.ejca.2020.04.038 |
2021 |
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration. |
SYK |
| 29 |
32784334 |
10.1097/CM9.0000000000000999 |
2021 |
TOSO interacts with SYK and enhances BCR pathway activation in chronic lymphocytic leukemia. |
SYK |
| 30 |
33020271 |
10.1073/pnas.2007946117 |
2021 |
Rewiring of B cell receptor signaling by Epstein-Barr virus LMP2A. |
SYK |
| 31 |
33089525 |
10.1111/ejh.13538 |
2021 |
A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia. |
SYK |
| 32 |
33259129 |
10.1111/jcmm.15851 |
2021 |
Prognostic and predictive value of a mRNA signature in peripheral T-cell lymphomas: A mRNA expression analysis. |
SYK |
| 33 |
33435587 |
10.3390/ijms22020592 |
2021 |
Precursor B-ALL Cell Lines Differentially Respond to SYK Inhibition by Entospletinib. |
SYK |
| 34 |
33615197 |
10.1016/j.isci.2021.102089 |
2021 |
Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways. |
SYK |
| 35 |
33639170 |
10.1016/j.jbc.2021.100465 |
2021 |
TNF receptor-associated factor 3 restrains B-cell receptor signaling in normal and malignant B cells. |
SYK |
| 36 |
33670716 |
10.3390/biom11020308 |
2021 |
Comparison of SYK Signaling Networks Reveals the Potential Molecular Determinants of Its Tumor-Promoting and Suppressing Functions. |
SYK |
| 37 |
33777680 |
10.1016/j.apsb.2020.10.021 |
2021 |
A multifunctional cross-validation high-throughput screening protocol enabling the discovery of new SHP2 inhibitors. |
SYK |
| 38 |
33782605 |
10.1038/s41588-021-00803-4 |
2021 |
Gain-of-function variants in SYK cause immune dysregulation and systemic inflammation in humans and mice. |
SYK |
| 39 |
33878293 |
10.1016/j.molcel.2021.03.043 |
2021 |
Developmental partitioning of SYK and ZAP70 prevents autoimmunity and cancer. |
SYK |
| 40 |
34043588 |
10.1172/JCI139675 |
2021 |
Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming. |
SYK |
| 41 |
34177947 |
10.3389/fimmu.2021.689472 |
2021 |
Resistance Mutations to BTK Inhibitors Originate From the NF-κB but Not From the PI3K-RAS-MAPK Arm of the B Cell Receptor Signaling Pathway. |
SYK |
| 42 |
34204843 |
10.3390/cancers13122958 |
2021 |
Constitutive PSGL-1 Correlates with CD30 and TCR Pathways and Represents a Potential Target for Immunotherapy in Anaplastic Large T-Cell Lymphoma. |
SYK |
| 43 |
34323286 |
10.1002/eji.202048968 |
2021 |
Bruton's tyrosine kinase inhibition induces rewiring of proximal and distal B-cell receptor signaling in mice. |
SYK |
| 44 |
34500771 |
10.3390/molecules26175340 |
2021 |
Influence of Vincristine, Clinically Used in Cancer Therapy and Immune Thrombocytopenia, on the Function of Human Platelets. |
SYK |
| 45 |
30333224 |
10.1158/1078-0432.CCR-18-1047 |
2020 |
Cerdulatinib Pharmacodynamics and Relationships to Tumor Response Following Oral Dosing in Patients with Relapsed/Refractory B-cell Malignancies. |
SYK |
| 46 |
30609049 |
10.1002/jmv.25381 |
2020 |
Epstein-Barr virus LMP2A utilizes Syk and PI3K to activate NF-κB in B-cell lymphomas to increase MIP-1α production. |
SYK |
| 47 |
30633573 |
10.1080/10428194.2018.1562180 |
2020 |
Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study. |
SYK |
| 48 |
30663686 |
10.3791/58439 |
2020 |
Myeloid Innate Signaling Pathway Regulation by MALT1 Paracaspase Activity. |
SYK |
| 49 |
30719267 |
10.1177/2040620718820510 |
2020 |
Novel treatment approaches and future perspectives in follicular lymphoma. |
SYK |
| 50 |
30819916 |
10.3324/haematol.2018.212811 |
2020 |
A B-cell receptor-related gene signature predicts response to ibrutinib treatment in mantle cell lymphoma cell lines. |
SYK |
| 51 |
30872780 |
10.1038/s41375-019-0442-8 |
2020 |
Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma. |
SYK |
| 52 |
31030752 |
10.1016/bs.pmbts.2019.02.013 |
2020 |
Mushroom polysaccharide lentinan for treating different types of cancers: A review of 12 years clinical studies in China. |
SYK |
| 53 |
31040105 |
10.1158/2159-8290.CD-18-1393 |
2020 |
Mechanisms of Lymphoma Clearance Induced by High-Dose Alkylating Agents. |
SYK |
| 54 |
31197205 |
10.1038/s41374-019-0262-5 |
2020 |
PD-L1 over-expression is driven by B-cell receptor signaling in diffuse large B-cell lymphoma. |
SYK |
| 55 |
31362927 |
10.1182/bloodadvances.2018016162 |
2020 |
Interplay between HGAL and Grb2 proteins regulates B-cell receptor signaling. |
SYK |
| 56 |
31545408 |
10.3892/ijo.2019.4882 |
2020 |
Genome profiling revealed the activation of IL2RG/JAK3/STAT5 in peripheral T‑cell lymphoma expressing the ITK‑SYK fusion gene. |
SYK |
| 57 |
31782972 |
10.1002/hon.2694 |
2020 |
New responsibilities for aged kinases in B-lymphomas. |
SYK |
| 58 |
31817853 |
10.3390/ijms20246175 |
2020 |
SYK Targeting Represents a Potential Therapeutic Option for Relapsed Resistant Pediatric <i>ETV6-RUNX1</i> B-Acute Lymphoblastic Leukemia Patients. |
SYK |
| 59 |
31943941 |
10.1002/art.41204 |
2020 |
Requirement of Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein 1 Protease Activity for Fcγ Receptor-Induced Arthritis, but Not Fcγ Receptor-Mediated Platelet Elimination, in Mice. |
SYK |
| 60 |
32005797 |
10.1038/s41408-020-0277-6 |
2020 |
SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas. |
SYK |
| 61 |
32481736 |
10.3390/cancers12061396 |
2020 |
Mechanisms of B Cell Receptor Activation and Responses to B Cell Receptor Inhibitors in B Cell Malignancies. |
SYK |
| 62 |
32620617 |
10.21873/anticanres.14367 |
2020 |
Pan- and Isoform-specific Inhibition of the Bromodomain and Extra-terminal Proteins and Evaluation of Synergistic Potential With Entospletinib in Canine Lymphoma. |
SYK |
| 63 |
32702393 |
10.1016/j.exphem.2020.07.005 |
2020 |
DEPTOR is a microRNA-155 target regulating migration and cytokine production in diffuse large B-cell lymphoma cells. |
SYK |
| 64 |
25506060 |
10.1016/j.ebiom.2014.10.019 |
2019 |
A PREVIOUSLY UNKNOWN UNIQUE CHALLENGE FOR INHIBITORS OF SYK ATP-BINDING SITE: ROLE OF SYK AS A CELL CYCLE CHECKPOINT REGULATOR. |
SYK |
| 65 |
28460620 |
10.2174/1568009617666170427110450 |
2019 |
CX-4945, a Selective Inhibitor of Casein Kinase 2, Synergizes with B Cell Receptor Signaling Inhibitors in Inducing Diffuse Large B Cell Lymphoma Cell Death. |
SYK |
| 66 |
29052597 |
10.1038/modpathol.2017.145 |
2019 |
SYK expression in monomorphic epitheliotropic intestinal T-cell lymphoma. |
SYK |
| 67 |
29246942 |
10.1158/1078-0432.CCR-17-2218 |
2019 |
Synergistic Targeting of the Regulatory and Catalytic Subunits of PI3Kδ in Mature B-cell Malignancies. |
SYK |
| 68 |
29340070 |
10.18632/oncotarget.22847 |
2019 |
A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models. |
SYK |
| 69 |
29472356 |
10.3324/haematol.2017.184325 |
2019 |
A B-cell receptor-related gene signature predicts survival in mantle cell lymphoma: results from the Fondazione Italiana Linfomi MCL-0208 trial. |
SYK |
| 70 |
29572158 |
10.1016/j.clml.2018.02.017 |
2019 |
A Phase I/II Trial of the Combination of Azacitidine and Gemtuzumab Ozogamicin for Treatment of Relapsed Acute Myeloid Leukemia. |
SYK |
| 71 |
29642007 |
10.1016/j.celrep.2018.03.069 |
2019 |
How Biophysical Forces Regulate Human B Cell Lymphomas. |
SYK |
| 72 |
29740433 |
10.3389/fimmu.2018.00787 |
2019 |
SYK Inhibition Induces Apoptosis in Germinal Center-Like B Cells by Modulating the Antiapoptotic Protein Myeloid Cell Leukemia-1, Affecting B-Cell Activation and Antibody Production. |
SYK |
| 73 |
29881386 |
10.3389/fimmu.2018.01136 |
2019 |
Ancient Origin of the CARD-Coiled Coil/Bcl10/MALT1-Like Paracaspase Signaling Complex Indicates Unknown Critical Functions. |
SYK |
| 74 |
29925955 |
10.1038/s41586-018-0290-0 |
2019 |
A multiprotein supercomplex controlling oncogenic signalling in lymphoma. |
SYK |
| 75 |
29934062 |
10.1016/j.clml.2018.05.022 |
2019 |
An Open-label, Phase II Trial of Entospletinib (GS-9973), a Selective Spleen Tyrosine Kinase Inhibitor, in Diffuse Large B-cell Lymphoma. |
SYK |
| 76 |
30183069 |
10.1111/bjh.15552 |
2019 |
An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma. |
SYK |
| 77 |
30217447 |
10.1016/j.bbrc.2018.09.019 |
2019 |
Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression. |
SYK |
| 78 |
30402490 |
10.1155/2018/6728128 |
2019 |
Gene Expression Profile Signature of Aggressive Waldenström Macroglobulinemia with Chromosome 6q Deletion. |
SYK |
| 79 |
30534553 |
10.1155/2018/1042597 |
2019 |
Bone Marrow Molecular Markers Associated with Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma. |
SYK |
| 80 |
30592080 |
10.1002/ajh.25387 |
2019 |
Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study. |
SYK |
| 81 |
30617194 |
10.1182/blood-2018-09-871418 |
2019 |
Genome-wide discovery of somatic coding and noncoding mutations in pediatric endemic and sporadic Burkitt lymphoma. |
SYK |
| 82 |
30777096 |
10.1186/s13046-019-1076-4 |
2019 |
Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma. |
SYK |
| 83 |
27297662 |
10.1038/ncomms11889 |
2018 |
Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. |
SYK |
| 84 |
27888629 |
10.18632/oncotarget.13557 |
2018 |
Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells. |
SYK |
| 85 |
28639315 |
10.1111/his.13287 |
2018 |
MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma. |
SYK |
| 86 |
28791394 |
10.3892/mmr.2017.7158 |
2018 |
Identification of key genes and pathways associated with classical Hodgkin lymphoma by bioinformatics analysis. |
SYK |
| 87 |
28933554 |
10.1021/acs.molpharmaceut.7b00710 |
2018 |
Rational Targeting of Cellular Cholesterol in Diffuse Large B-Cell Lymphoma (DLBCL) Enabled by Functional Lipoprotein Nanoparticles: A Therapeutic Strategy Dependent on Cell of Origin. |
SYK |
| 88 |
29125235 |
10.1002/cam4.1257 |
2018 |
Comparison of the mRNA expression profile of B-cell receptor components in normal CD5-high B-lymphocytes and chronic lymphocytic leukemia: a key role of ZAP70. |
SYK |
| 89 |
29279549 |
10.3960/jslrt.17019 |
2018 |
Recent Progress in the Understanding of Angioimmunoblastic T-cell Lymphoma. |
SYK |
| 90 |
29781323 |
10.1080/14728214.2018.1479396 |
2018 |
Targeting the B-cell receptor pathway: a review of current and future therapies for non-Hodgkin's lymphoma. |
SYK |
| 91 |
29855199 |
10.1080/13543784.2018.1482273 |
2018 |
Targeting the B cell receptor pathway in non-Hodgkin lymphoma. |
SYK |
| 92 |
30066853 |
10.3892/ijo.2018.4513 |
2018 |
Anti-adult T‑cell leukemia/lymphoma activity of cerdulatinib, a dual SYK/JAK kinase inhibitor. |
SYK |
| 93 |
30135222 |
10.1128/mSphereDirect.00378-18 |
2018 |
Spleen Tyrosine Kinase Inhibitor TAK-659 Prevents Splenomegaly and Tumor Development in a Murine Model of Epstein-Barr Virus-Associated Lymphoma. |
SYK |
| 94 |
26354285 |
10.1002/hon.2251 |
2017 |
Concomitant high expression of Toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma. |
SYK |
| 95 |
26847027 |
10.1038/leu.2016.9 |
2017 |
Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. |
SYK |
| 96 |
26968534 |
10.1182/blood-2015-12-683516 |
2017 |
Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. |
SYK |
| 97 |
27264434 |
10.1111/cbdd.12798 |
2017 |
3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors. |
SYK |
| 98 |
27297792 |
10.1182/blood-2016-03-707141 |
2017 |
Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma. |
SYK |
| 99 |
27406873 |
10.1002/jcph.794 |
2017 |
PRT062607 Achieves Complete Inhibition of the Spleen Tyrosine Kinase at Tolerated Exposures Following Oral Dosing in Healthy Volunteers. |
SYK |
| 100 |
27432944 |
10.1084/jem.20151932 |
2017 |
E3 ubiquitin ligase Cbl-b negatively regulates C-type lectin receptor-mediated antifungal innate immunity. |
SYK |
Datasets
Models
